Efzofitimod for Pulmonary Sarcoidosis Highlighted in Best of CHEST Journals at CHEST 2024

SAN DIEGO, Oct. 08, 2024 – aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology enterprise focused on pioneering medicines derived from its unique tRNA synthetase platform, announced that its leading therapeutic candidate, efzofitimod, will be highlighted in the Best of CHEST Journals session at the CHEST 2024 Annual Meeting in Boston, MA, from October 6 – 9, 2024.

Dr. Sanjay S. Shukla, President and CEO of aTyr, expressed satisfaction with the recognition of efzofitimod at this prestigious session. Dr. Shukla emphasized the significance of the Phase 1b/2a study, previously published in the CHEST journal, which demonstrated efzofitimod's ability to reduce or, in some cases, eliminate the use of steroids in patients while effectively managing symptoms. According to Dr. Shukla, these results mark an important development towards a new treatment for sarcoidosis.

The presentation, titled "Efzofitimod for the Treatment of Pulmonary Sarcoidosis," will be delivered by Dr. Daniel A. Culver, Chair of the Division of Pulmonary Medicine at the Cleveland Clinic. The session will take place on Tuesday, October 8, 2024, from 4:00 p.m. to 4:20 p.m. EDT at the Convention Center 256. Dr. Culver's presentation will cover data supporting efzofitimod's efficacy in treating pulmonary sarcoidosis, including key findings from the Phase 1b/2a study on efficacy endpoints like steroid reduction, lung function, sarcoidosis symptoms, and inflammatory biomarkers. The session will also include data from the European Respiratory Journal's post hoc analysis of the study, which evaluated the time-to-first-relapse and relapse rate for steroid use.

Currently, efzofitimod is undergoing evaluation in the global pivotal Phase 3 EFZO-FIT™ study, involving 268 patients with pulmonary sarcoidosis. Topline results from this study are anticipated in the third quarter of 2025.

Efzofitimod stands out as a first-in-class biologic immunomodulator under clinical investigation for treating interstitial lung disease (ILD), a category of immune-mediated conditions leading to lung inflammation and fibrosis. As a therapy derived from tRNA synthetase, efzofitimod targets activated myeloid cells through neuropilin-2 to alleviate inflammation without suppressing the immune system and potentially halting fibrosis progression. Besides the Phase 3 EFZO-FIT™ study, aTyr is also assessing efzofitimod in the Phase 2 EFZO-CONNECT™ study for patients with systemic sclerosis (SSc)-related ILD. These ILD forms have limited treatment options, underscoring the need for safer, more effective, and disease-modifying therapies that enhance patient outcomes.

aTyr Pharma is a clinical stage biopharmaceutical company that leverages evolutionary insights to transform tRNA synthetase biology into novel treatments for fibrosis and inflammation. tRNA synthetases are ancient and essential proteins that have evolved unique domains regulating diverse pathways outside human cells. aTyr’s platform focuses on discovering new therapeutic intervention points by exploring signaling pathways driven by its proprietary library of domains from all 20 tRNA synthetases. Efzofitimod, the company's leading therapeutic candidate, is a pioneering biologic immunomodulator in clinical development for treating interstitial lung disease, a group of immune-mediated disorders causing lung inflammation and fibrosis.